LCM
AKTS

Laurion Capital Management’s Aktis Oncology AKTS Stock Holding History

Laurion Capital Management’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100,000
Closed -$1.79M – 575
2026
Q1 		$1.79M Buy
+100,000
New +$1.94M 0.08% 222

Other funds holding AKTS

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Laurion Capital Management's AKTS Position: Q2 2026 in Review

Laurion Capital Management sold out of Aktis Oncology (AKTS) in Q2 2026, closing a stake of 100,000 shares — an estimated $1.79M sold.

Laurion Capital Management first reported a position in AKTS in Q1 2026 and held it in 1 quarter. The position peaked at $1.79M in Q1 2026. 113 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

  • Laurion Capital Management reported no remaining Aktis Oncology position as of Q2 2026 after selling out during the quarter.
  • Laurion Capital Management sold 100,000 Aktis Oncology shares in Q2 2026, an estimated $1.79M.
  • Laurion Capital Management first reported a position in Aktis Oncology in Q1 2026 and held it in 1 quarter.
  • Laurion Capital Management's Aktis Oncology position peaked at $1.79M in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.